Related Experiment Video
Updated: Jun 21, 2026

Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling
Published on: August 1, 2016
Myocardial Na,K-ATPase: Clinical aspects
1Laboratory for Molecular Cardiology, Copenhagen Heart Arrhythmia Research Centre, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Insights
Digitalis glycosides, like digoxin, are crucial for treating heart failure by improving heart function and hemodynamics. Maintaining proper potassium levels is vital for Na,K-ATPase activity and overall cardiac health.
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Background:
- Heart failure is associated with a significant decrease in myocardial Na,K-ATPase concentration, correlating with reduced heart function.
- Digitalis glycosides bind specifically to Na,K-ATPase, enabling its quantification and serving as a therapeutic agent in heart failure.
- Various medications used for heart failure, including diuretics and ACE inhibitors, can influence Na,K-ATPase activity and potassium homeostasis.
Purpose of the Study:
- To explore the role of Na,K-ATPase in heart failure and its modulation by therapeutic interventions.
- To investigate the impact of digitalis glycosides and other heart failure medications on Na,K-ATPase activity and potassium regulation.
- To highlight the importance of Na,K pump modulation in the context of sodium, potassium, and calcium balance in cardiac disease.
Main Methods:
- Utilizing the specific binding of digitalis glycosides to Na,K-ATPase for accurate quantification.
- Analyzing myocardial biopsies from heart failure patients to assess Na,K-ATPase concentration.
- Reviewing the effects of various drugs (diuretics, ACE inhibitors, spironolactone) and physiological conditions (hyperaldosteronism, potassium depletion) on Na,K-ATPase activity.
Main Results:
- Total Na,K-ATPase concentration is reduced by approximately 40% in heart failure patients.
- Digoxin occupies about 30% of remaining Na,K pumps during digitalization.
- Potassium loss from diuretic therapy decreases Na,K-ATPase, while ACE inhibitors may stimulate it; hyperaldosteronism also reduces activity.
Conclusions:
- Na,K-ATPase plays a critical role in heart function, and its modulation by disease and medication is significant.
- Digitalis glycosides are recommended for heart failure patients with persistent symptoms, improving hemodynamics and serving as safe oral inotropic agents.
- Maintaining extracellular potassium homeostasis is crucial, with a recommendation for resting plasma potassium levels around 4 mmol/L to optimize Na,K pump function and prevent arrhythmias.
Abstract:
The specific binding of digitalis glycosides to Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased by around 40%; a correlation exists between a decrease in heart function and a decrease in Na,K-ATPase concentration. During digitalization, around 30% of remaining pumps are occupied by digoxin. Myocardial Na,K-ATPase is also influenced by other drugs used for the treatment of heart failure. Thus, potassium loss during diuretic therapy has been found to reduce myocardial Na,K-ATPase, whereas angiotensin-converting enzyme inhibitors may stimulate Na,K pump activity. Furthermore, hyperaldosteronism induced by heart failure has been found to decrease Na,K-ATPase activity. Accordingly, treatment with the aldosterone antagonist, spironolactone, may also influence Na,K-ATPase activity. The importance of Na,K pump modulation with heart disease, inhibition in digitalization and other effects of medication should be considered in the context of sodium, potassium and calcium regulation. It is recommended that digoxin be administered to heart failure patients who, after institution of mortality-reducing therapy, still have heart failure symptoms, and that the therapy be continued if symptoms are revealed or reduced. Digitalis glycosides are the only safe inotropic drugs for oral use that improve hemodynamics in heart failure.An important aspect of myocardial Na,K pump affection in heart disease is its influence on extracellular potassium (K(e)) homeostasis. Two important aspects should be considered: potassium handling among myocytes, and effects of potassium entering the extracellular space of the heart via the bloodstream. It should be noted that both of these aspects of K(e) homeostasis are affected by regulatory aspects, eg, regulation of the Na,K pump by physiological and pathophysiological conditions, as well as by medical treatments. Digitalization has been shown to affect both parameters. Furthermore, in experimental animals, potassium loading and depletion are found to significantly affect K(e) handling. The effects of potassium depletion are of special interest because this condition often occurs in patients treated with diuretics. In human congenital long QT syndrome caused by mutations in genes coding for potassium channels, exercise and potassium depletion are well known for their potential to elicit arrhythmias and sudden death. There is a need for further evaluation of the dynamic aspects of potassium handling in the heart, as well as in the periphery. It is recommended that resting plasma potassium be maintained at around 4 mmol/L.
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Heart Failure Drugs: Inotropic Agents
Acute Coronary Syndrome I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
ATP Synthase: Mechanism
